Capricor Therapeutics Prices 6M Share Offering at $25, Raising $150M
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 58 minutes ago0mins
- Public Offering Pricing: Capricor Therapeutics has priced its public offering of 6 million shares at $25 per share, aiming to raise a total of $150 million, reflecting strong market confidence in its biotechnology products.
- Underwriter Selection: Piper Sandler and Oppenheimer & Co. are acting as joint book-running managers for the offering, with H.C. Wainwright & Co. as co-manager, enhancing the market credibility of the issuance.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for the continued development of product candidates, manufacturing, working capital, and general corporate purposes, indicating a strong focus on future R&D and strategic positioning.
- Compliance Assurance: The offering is conducted under an effective S-3 registration statement, ensuring compliance and providing transparent information to investors, which reduces investment risks and enhances market trust.
CAPR.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CAPR
Wall Street analysts forecast CAPR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 21.25 USD with a low forecast of 13.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.960
Low
13.00
Averages
21.25
High
29.00
Current: 29.960
Low
13.00
Averages
21.25
High
29.00
Maxim
Maxim
Buy
maintain
$25 -> $50
2025-12-04
New
Reason
Maxim
Maxim
Price Target
$25 -> $50
2025-12-04
New
maintain
Buy
Reason
Maxim raised the firm's price target on Capricor Therapeutics to $50 from $25 and keeps a Buy rating on the shares. The firm cites the company's top-line data from the HOPE-3 trial for Deramiocel ) in Duchenne muscular dystrophy meeting both the primary endpoint of PuL2.0 and the key secondary endpoint of left ventricular ejection fraction at statistically significant levels, as well as other measures, the analyst tells investors in a research note. The data demonstrated both skeletal and cardiac benefits, which tracked with prior observations in both the HOPE-2 phase 2 and HOPE-2 open-label extension, the firm added.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$24 -> $60
2025-12-03
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$24 -> $60
2025-12-03
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Capricor Therapeutics to $60 from $24 and keeps a Buy rating on the shares. Capricor rebounded from its July 2025 Complete Response Letter with a decisive clinical win, meeting its primary PUL v2.0 endpoint and the prospectively triggered Left Ventricular Ejection Fraction analysis, positioning its therapy to reach Duchenne muscular dystrophy patients, the analyst tells investors in a research note. With 78% of participants having underlying cardiomyopathy-addressing FDA concerns about sample size-and a conservative approval expectation of mid-2026, shares are likely to trade well into year-end, the firm says.
Alliance Global
NULL -> Buy
maintain
$16 -> $48
2025-12-03
New
Reason
Alliance Global
Price Target
$16 -> $48
2025-12-03
New
maintain
NULL -> Buy
Reason
Alliance Global raised the firm's price target on Capricor Therapeutics to $48 from $16 and keeps a Buy rating on the shares after the company read out topline data for their pivotal Phase 3 HOPE-3 trial of Deramiocel in 106 Duchenne Muscular Dystrophy patients. These data were unequivocally and wholly positive, in the firm's view. Alliance Global is removing its speculative tag.
Roth Capital
Boobalan Pachaiyappan
Buy
maintain
$12 -> $13
2025-11-11
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$12 -> $13
2025-11-11
maintain
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan raised the firm's price target on Capricor Therapeutics to $13 from $12 and keeps a Buy rating on the shares. At the very least, the firm expects Phase 3 HOPE-3 results anticipated in Q4 tot show evidence of cardiac improvements during which case Capricor may pressure the agency to exercise regulatory flexibility to approve Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy, the analyst tells investors in a research note. The firm added that its models assumed Deramiocel approval in this sub-disease area.
See All Ratings
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contributed to Capricor's stock surge following the HOPE-3 trial results?
Why did Martin Shkreli criticize Capricor's Phase 3 trial data presentation?
How might Capricor's stock perform after submitting the BLA response to the FDA?
What are the chances of FDA approval for Deramiocel based on HOPE-3 results?